the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Official Title Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Principal Investigator Stadler, Walter
Brief Summary This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab
Gender All
Ages 18 Years
Enrollment 58
Accepts Healthy Volunteers No
Lead Sponsor Dana-Farber Cancer InstituteOther
Collaborator Bristol-Myers SquibbIndustry
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name David F McDermott, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Renal Cancer
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI